MyPrEP Plus: Development and Pilot Testing of Novel Preexposure Prophylaxis Decision Support Tools for Transgender Women
NCT ID: NCT07146139
Last Updated: 2025-08-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
2 participants
INTERVENTIONAL
2023-03-18
2025-03-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services
NCT01781806
Stick2PrEP Cisgender Women and Trans Individuals
NCT05165745
Accelerated PrEP Access for Black MSM and TW
NCT04329442
Long-acting Biomedical HIV Prevention in Transgender Women
NCT03856580
Pre-Exposure Prophylaxis for Transgender Women in the US and South America
NCT04742491
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants in each group will start out by completing a baseline questionnaire that will ask about demographics, behaviors, and PrEP and Doxy-PEP knowledge. Each participant will be followed for three months while deciding to take PrEP or actively taking PrEP. At the end of three months, participants will be administered another survey which will assess PrEP uptake, change in PrEP and Doxy-PEP knowledge, and how well the MyPrEP Plus package helped with starting and staying on PrEP. Around 20 participants in the experimental condition will be invited for an in-depth interview to discuss their experience using the MyPrEP Plus package.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental Conditon: MyPrEP Plus
The intervention administered in the experimental condition includes PrEP decisional and adherence support with the MyPrEP Plus package.
MyPrEP Plus Package
Participants receiving the MyPrEP Plus Package will utilize the interactive MyPrEP website to learn about PrEP and the various kinds of PrEP available as well as information about Doxy-PEP. While on PrEP, participants will be able sign up for PrEPmate, a tool designed to support PrEP adherence.
Control Condition: Standard of Care
Participants randomized to the control condition will receive PrEP support through the standard of care.
Standard of Care (SOC)
Participants in the control condition will receive PrEP support according to local standard of care while using the website pleaseprepme.org.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MyPrEP Plus Package
Participants receiving the MyPrEP Plus Package will utilize the interactive MyPrEP website to learn about PrEP and the various kinds of PrEP available as well as information about Doxy-PEP. While on PrEP, participants will be able sign up for PrEPmate, a tool designed to support PrEP adherence.
Standard of Care (SOC)
Participants in the control condition will receive PrEP support according to local standard of care while using the website pleaseprepme.org.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Identify as a transgender woman or woman and was assigned male sex at birth
* Are not currently on PrEP in the last three months and interested in learning more about PrEP
* Able to successfully send and receive text messages
* HIV negative by self-report
* Are able to speak, read and write in English or Spanish
* Report any of the following in the last 12 months:
* Having anal or vaginal sex with a person assigned male at birth
* Exchange of sex for money, goods, or services
* Received a diagnosis of a sexually transmitted infection
* Sharing injection equipment
* Are able and willing to provide written informed consent and participate for the duration of the study
Exclusion Criteria
* Of any medical, psychiatric, or social condition that in the opinion of the investigator would preclude participation or their ability to remain in the trial
* Study site staff member
18 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Public Health Foundation Enterprises, Inc.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Susan Buchbinder, MD
Role: PRINCIPAL_INVESTIGATOR
Bridge HIV, San Francisco Department of Public Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bridge HIV, San Francisco Department of Public Health
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00083027
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.